Everything we've seen

1. ·Nov 15, 11:32 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

2. ·Nov 15, 11:17 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

3. ·Nov 15, 11:02 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

4. ·Nov 15, 10:47 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

5. ·Nov 15, 10:32 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

6. ·Nov 15, 10:17 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

7. ·Nov 15, 10:02 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

8. ·Nov 15, 9:47 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

9. ·Nov 15, 9:32 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

10. ·Nov 15, 9:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

11. ·Nov 15, 9:02 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

12. ·Nov 15, 8:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

13. ·Nov 15, 8:32 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

14. ·Nov 15, 8:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

15. ·Nov 15, 8:03 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

16. ·Nov 15, 7:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

17. ·Nov 15, 7:32 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

18. ·Nov 15, 7:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

19. ·Nov 15, 7:02 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

20. ·Nov 15, 6:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

21. ·Nov 15, 6:32 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

22. ·Nov 15, 6:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

23. ·Nov 15, 6:03 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

24. ·Nov 15, 5:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

25. ·Nov 15, 5:32 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

26. ❖Nov 13, 12:30 PMnewsvia finnhub

    Here's How Much $100 Invested In ResMed 10 Years Ago Would Be Worth Today

    ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 1.92% on an annualized basis producing an average annual return of 15.08%. Currently, ResMed has a market capitalization of $33.60 billion. Buying

27. ❖Nov 13, 10:15 AMnewsvia finnhub

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

28. ?Nov 12, 1:30 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is up 1.54% today, a modest but meaningful move with 135 minutes remaining — enough time for further directional movement. The move is below the 2-5% threshold that would signal strong institutional conviction, so it reads more as ordinary momentum than a high-conviction breakout. No headlines are available to explain the move, which is neutral (not a disqualifier per the framework). The macro context shows T10YIE at 2.2, running 1.7σ below its 24-month trend — this is a low real-rate / low inflation expectations environment, which is broadly supportive for long-duration sensitive sectors and growth-oriented medtech names like RMD. Lower discount rates favor RMD's valuation profile, providing a mild tailwind to continuation. With no reversal signals, no adverse macro pressure, and adequate time remaining, the base case leans slightly toward continuation. However, the modest magnitude of the move and absence of a clear catalyst limit confidence, keeping the probability near the lower bound of the continuation range.

29. !Nov 12, 1:30 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is up 1.54% today, a modest but meaningful move with 135 minutes remaining — enough time for further directional movement. The move is below the 2-5% threshold that would signal strong institutional conviction, so it reads more as ordinary momentum than a high-conviction breakout. No headlines are available to explain the move, which is neutral (not a disqualifier per the framework). The macro context shows T10YIE at 2.2, running 1.7σ below its 24-month trend — this is a low real-rate / low inflation expectations environment, which is broadly supportive for long-duration sensitive sectors and growth-oriented medtech names like RMD. Lower discount rates favor RMD's valuation profile, providing a mild tailwind to continuation. With no reversal signals, no adverse macro pressure, and adequate time remaining, the base case leans slightly toward continuation. However, the modest magnitude of the move and absence of a clear catalyst limit confidence, keeping the probability near the lower bound of the continuation range.

30. ?Nov 12, 12:25 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is up 1.59% today, a modest but real move suggesting some genuine buying interest. No headlines are available to explain the move, which is not unusual — institutional flow often precedes or operates without news. The macro context shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend, indicating a low-inflation-expectations environment. RMD is a medical device company (sleep apnea/respiratory), which is a long-duration-sensitive sector — lower inflation expectations are mildly supportive for growth/quality names like RMD as discount rates compress. With 200 minutes remaining (over 3 hours), there is ample time for continuation. However, the move magnitude (1.59%) is below the threshold where momentum is typically self-sustaining, and without a clear catalyst or volume confirmation signal, conviction is limited. No reversal pattern is evident. On balance, the setup offers a mild lean toward continuation — supportive macro, sufficient time, no fade signal — but not enough to warrant high conviction. Assigning a slight positive edge consistent with ordinary momentum in the absence of countervailing pressure.

31. !Nov 12, 12:25 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is up 1.59% today, a modest but real move suggesting some genuine buying interest. No headlines are available to explain the move, which is not unusual — institutional flow often precedes or operates without news. The macro context shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend, indicating a low-inflation-expectations environment. RMD is a medical device company (sleep apnea/respiratory), which is a long-duration-sensitive sector — lower inflation expectations are mildly supportive for growth/quality names like RMD as discount rates compress. With 200 minutes remaining (over 3 hours), there is ample time for continuation. However, the move magnitude (1.59%) is below the threshold where momentum is typically self-sustaining, and without a clear catalyst or volume confirmation signal, conviction is limited. No reversal pattern is evident. On balance, the setup offers a mild lean toward continuation — supportive macro, sufficient time, no fade signal — but not enough to warrant high conviction. Assigning a slight positive edge consistent with ordinary momentum in the absence of countervailing pressure.

32. ❖Nov 11, 11:38 AMnewsvia finnhub

    Oura makes bet on AI in healthcare with $625M Counsel Health buy

    The planned acquisition comes as wearable firms push to up their healthcare offerings.

33. ❖Nov 10, 1:31 PMnewsvia finnhub

    INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

    Inspire Medical shares have rallied 12.1% in three months, but reimbursement hurdles and weak revenues raise questions about whether the gains can continue.

34. ?Nov 10, 11:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is down 1.66% today with no attributable headlines. The move is real but below the 2-5% threshold that would indicate high-conviction directional flow. With 280 minutes remaining (essentially a full trading day ahead), there is ample time for continuation, but also ample time for mean reversion. The macro context (elevated DFF at 2.0σ above trend) is modestly negative for growth/medtech names like RMD, as higher rates compress multiples and increase discount rates on future cash flows — a mild headwind that could sustain selling pressure. However, the effect is indirect and modest. No news catalyst means we cannot distinguish institutional distribution from normal intraday noise. The magnitude of the move (~1.66%) is below the level that typically signals sustained momentum continuation. Taken together, the balance of evidence offers a marginal lean toward continuation given the rate environment headwind and absence of a reversal signal, but confidence is low. Setting probability at exactly 0.5 — the base case for a directionless read with mild supportive macro context.

35. !Nov 10, 11:05 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is down 1.66% today with no attributable headlines. The move is real but below the 2-5% threshold that would indicate high-conviction directional flow. With 280 minutes remaining (essentially a full trading day ahead), there is ample time for continuation, but also ample time for mean reversion. The macro context (elevated DFF at 2.0σ above trend) is modestly negative for growth/medtech names like RMD, as higher rates compress multiples and increase discount rates on future cash flows — a mild headwind that could sustain selling pressure. However, the effect is indirect and modest. No news catalyst means we cannot distinguish institutional distribution from normal intraday noise. The magnitude of the move (~1.66%) is below the level that typically signals sustained momentum continuation. Taken together, the balance of evidence offers a marginal lean toward continuation given the rate environment headwind and absence of a reversal signal, but confidence is low. Setting probability at exactly 0.5 — the base case for a directionless read with mild supportive macro context.

36. ?Nov 6, 2:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is down 2.57% with 70 minutes remaining — a meaningful move, but several factors temper continuation probability. No headlines are driving the move, which cuts both ways: without a catalyst narrative, the move is harder to sustain into the close as short-term sellers may have already exhausted their urgency. The macro context (elevated 30-year mortgage rate at 7.18%, 1.9σ above trend) is not directly relevant to RMD (a medical device company focused on sleep apnea/respiratory), so there is no sector tailwind feeding this move. With 70 minutes left, there is meaningful time for a continuation, but that also means more time for a mean-reversion bounce — institutional desks often fade intraday lows in the absence of a fresh catalyst, particularly in large-cap medtech names. The move sits at the lower boundary of the 2-5% range where conviction is real but not extreme. Absent any sector rotation, news, or macro alignment supporting further selling, this setup does not meet the ≥0.5 threshold needed to lean into the downside continuation. Slight lean toward fade/stabilization into the close.

37. !Nov 6, 2:35 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    RMD is down 2.57% with 70 minutes remaining — a meaningful move, but several factors temper continuation probability. No headlines are driving the move, which cuts both ways: without a catalyst narrative, the move is harder to sustain into the close as short-term sellers may have already exhausted their urgency. The macro context (elevated 30-year mortgage rate at 7.18%, 1.9σ above trend) is not directly relevant to RMD (a medical device company focused on sleep apnea/respiratory), so there is no sector tailwind feeding this move. With 70 minutes left, there is meaningful time for a continuation, but that also means more time for a mean-reversion bounce — institutional desks often fade intraday lows in the absence of a fresh catalyst, particularly in large-cap medtech names. The move sits at the lower boundary of the 2-5% range where conviction is real but not extreme. Absent any sector rotation, news, or macro alignment supporting further selling, this setup does not meet the ≥0.5 threshold needed to lean into the downside continuation. Slight lean toward fade/stabilization into the close.

38. ❖Nov 6, 1:30 PMnewsvia finnhub

    Dividend Champion, Contender, And Challenger Highlights: Week of November 8

    Get the latest dividend activity for Dividend Champions, Contenders, and Challengers. Read this week's list here.

39. ?Nov 5, 1:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is down 2.46% with 130 minutes remaining, a meaningful intraday move suggesting real selling pressure from institutional flow. No news catalyst is present, which is neutral per framework guidance — absence of headline does not negate momentum. The macro context (DFF 2.1σ above trend) reflects elevated rates, which is modestly negative for high-multiple healthcare/medtech names like RMD as discount rates remain pressured. However, several factors temper conviction: (1) no clear news driver means the move could be technical or sector rotation that fades; (2) with 130 minutes left there is time for reversal but also time for continuation; (3) elevated rates context is not acutely new information. On balance, momentum favors mild continuation of the downside into the close — the selling flow has not been contradicted by any bullish catalyst — but the setup is ordinary rather than high-conviction, warranting a probability just above the 0.5 threshold.

40. !Nov 5, 1:35 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is down 2.46% with 130 minutes remaining, a meaningful intraday move suggesting real selling pressure from institutional flow. No news catalyst is present, which is neutral per framework guidance — absence of headline does not negate momentum. The macro context (DFF 2.1σ above trend) reflects elevated rates, which is modestly negative for high-multiple healthcare/medtech names like RMD as discount rates remain pressured. However, several factors temper conviction: (1) no clear news driver means the move could be technical or sector rotation that fades; (2) with 130 minutes left there is time for reversal but also time for continuation; (3) elevated rates context is not acutely new information. On balance, momentum favors mild continuation of the downside into the close — the selling flow has not been contradicted by any bullish catalyst — but the setup is ordinary rather than high-conviction, warranting a probability just above the 0.5 threshold.

41. ❖Nov 5, 8:00 AMnewsvia finnhub

    Don’t Lose Sleep Over GLP-1s: Why ResMed Stock Is a Bargain

    ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.

42. ❖Nov 4, 9:52 PMnewsvia finnhub

    Top 10 High Growth Dividend Stocks For November 2026

43. ?Nov 4, 9:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

44. ?Nov 3, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

45. ?Nov 3, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

46. ?Nov 3, 12:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

47. ?Nov 3, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

48. ?Nov 3, 9:50 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is down 3.73% today with no attributable headline, suggesting institutional selling or sector rotation pressure rather than a news-driven event. The macro context shows DFF elevated 2.2σ above trend, which is moderately negative for rate-sensitive healthcare equipment names like RMD as higher rates compress multiples and increase cost of capital. With 355 minutes remaining (essentially a full trading session still ahead), there is ample time for the move to continue. However, the absence of a catalyst and the size of the move (~3.73%) introduce mean-reversion risk — at this magnitude, bargain hunters and algorithmic mean-reversion strategies may step in. No reversal pattern is evident from the data provided, and the move is large enough to represent real conviction from sellers. Balancing the meaningful downward momentum, rate-headwind macro backdrop, and ample time remaining against the lack of a specific catalyst and mean-reversion risk, a modest continuation probability is warranted. Taking the trade with tight stops given bounded downside risk.

49. !Nov 3, 9:50 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    RMD is down 3.73% today with no attributable headline, suggesting institutional selling or sector rotation pressure rather than a news-driven event. The macro context shows DFF elevated 2.2σ above trend, which is moderately negative for rate-sensitive healthcare equipment names like RMD as higher rates compress multiples and increase cost of capital. With 355 minutes remaining (essentially a full trading session still ahead), there is ample time for the move to continue. However, the absence of a catalyst and the size of the move (~3.73%) introduce mean-reversion risk — at this magnitude, bargain hunters and algorithmic mean-reversion strategies may step in. No reversal pattern is evident from the data provided, and the move is large enough to represent real conviction from sellers. Balancing the meaningful downward momentum, rate-headwind macro backdrop, and ample time remaining against the lack of a specific catalyst and mean-reversion risk, a modest continuation probability is warranted. Taking the trade with tight stops given bounded downside risk.

50. ❖Nov 3, 6:16 AMnewsvia finnhub

    ResMed: A Quality Compounder, But Not Yet A Bargain

    ResMed is a Hold, valuation offers a low margin of safety despite strong long-term fundamentals and recurring revenue streams. Read more on RMD stock here.

51. ?Nov 2, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

52. ?Nov 2, 9:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

53. ❖Nov 2, 4:33 AMnewsvia finnhub

    ResMed: 3 Key Takeaways for Long-Term Investors

    Manufacturing gains are lifting margins faster than revenue growth, signaling operational leverage ahead.

54. ❖Nov 1, 8:23 PMnewsvia finnhub

    What Sent ResMed Stock Lower?

    For questions about this article or underlying research, email help@trefis.com.

55. ❖Oct 31, 7:07 PMnewsvia finnhub

    RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscape

    Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.

56. ❖Oct 31, 7:00 AMnewsvia finnhub

    ResMed (NYSE:RMD) Delivers Quality Dividend Strength for Income Investors

    ResMed (RMD) passes a quality dividend screen with a 7/10 dividend rating, strong profitability, and healthy balance sheet despite a modest 1.25% yield.

57. ✓Oct 30, 4:21 PMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    RMD (ResMed) is a high-quality medical device company in the sleep apnea/respiratory care space. The 10.1% dip from its 30-day high appears to be macro/market-driven rather than company-specific, given today's broad market selloff (SPY -1.77%, QQQ -3.48%, VXX +10.28%) and the absence of any negative news headlines or 8-K disclosures pointing to fundamental deterioration. Health Care (XLV) is the top-ranked sector by 30-day relative strength (+8.14pts vs SPY), suggesting the sector remains in favor and the dip is likely a broad risk-off event. The single insider sale (400 shares, General Counsel) is modest and likely routine/10b5-1, not alarming. Next earnings are 89 days away, removing binary event risk for the trade window.

58. ?Oct 30, 4:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] RMD is a high-quality medical device company (sleep apnea/respiratory care) in the top-ranked Health Care sector, which has significantly outperformed SPY over both 5d (+0.80pts) and 30d (+8.14pts), suggesting the ~10% dip is more idiosyncratic or broad-market-driven than sector-specific. Today's broad market selloff (SPY -1.77%, QQQ -3.48%, VIX spiking via VXX +10.28%) likely explains much of the recent weakness. No fundamental deterioration is evident — the 10-Q and 8-K filings show no red flags in the available data, and the single insider sale of 400 shares (~$102K) by the General Counsel is modest and likely routine/10b5-1. Earnings are 89 days away, providing a clean runway for mean reversion.

59. ❖Oct 30, 3:16 PMnewsvia finnhub

    ResMed (RMD) Looks Fully Valued After Another Earnings Beat

    ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health tools. ResMed’s share price has climbed 13.5% over the past month and 19.8% across the last 90 days, while a 73.5% three year total shareholder return indicates that the recent earnings beat and ongoing dividend payments are reinforcing longer term momentum. Scan how ResMed’s...

60. ❖Oct 30, 2:06 PMnewsvia finnhub

    S&P 500 Unusual Volume Movers for Oct. 30, 2026

    S&P 500 unusual-volume screen for Oct. 30, 2026: Reddit fell 30.15% on heavy volume, Global Payments rose 10.41%, and several other stocks traded above average.

61. ❖Oct 30, 12:37 PMnewsvia finnhub

    Citigroup Maintains Neutral on ResMed, Raises Price Target to $270

    Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.

62. ❖Oct 30, 11:00 AMnewsvia finnhub

    ResMed (RMD) Q1 2027 Earnings Call Transcript

    Sleep device revenue grew 6% as AI tools boost therapy compliance and partnerships expand.

63. ❖Oct 30, 9:08 AMnewsvia finnhub

    RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288

    RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.

64. ❖Oct 30, 8:57 AMnewsvia finnhub

    Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250

    Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.

65. ❖Oct 30, 8:30 AMnewsvia finnhub

    ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say

    Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

66. ❖Oct 30, 8:30 AMnewsvia finnhub

    ResMed Inc. Q1 2027 Earnings Call Summary

    Moby summary of ResMed Inc.'s Q1 2027 earnings call

67. ❖Oct 30, 7:14 AMnewsvia finnhub

    What ResMed (RMD) Said on Its Q1 Earnings Call

    ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earning

68. ❖Oct 30, 6:28 AMnewsvia finnhub

    RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

    ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.

69. ❖Oct 30, 4:45 AMnewsvia finnhub

    Keybanc Maintains Overweight on ResMed, Raises Price Target to $277

    Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.

70. ❖Oct 30, 12:21 AMnewsvia finnhub

    ResMed Inc. Reports Q1 Fiscal Year 2027 Revenue of $1.4 billion and Declares Quarterly Cash Dividend of $0.66 per share

71. ❖Oct 29, 8:02 PMnewsvia finnhub

    ResMed Inc. 2027 Q1 - Results - Earnings Call Presentation

    2026-10-30. The following slide deck was published by ResMed Inc.

72. ❖Oct 29, 4:58 PMnewsvia finnhub

    ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript

    ResMed Inc. (RMD) Q1 2027 Earnings Call October 29, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Communications & Investor Relations...

73. ❖Oct 29, 4:53 PMnewsvia finnhub

    ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026

    Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q1 2027), with revenue rising 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.

74. ❖Oct 29, 4:35 PMnewsvia finnhub

    ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

    ResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

75. ❖Oct 29, 4:16 PMnewsvia finnhub

    ResMed: Fiscal Q1 Earnings Snapshot

    SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $418.

76. ❖Oct 29, 4:05 PMnewsvia finnhub

    Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

    Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basisQ1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1 Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarte

77. ❖Oct 29, 1:46 PMnewsvia finnhub

    ResMed Q1 2027 Earnings Call Transcript

    ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

78. ❖Oct 29, 1:31 PMnewsvia finnhub

    ResMed Sees FY2027 Adj EPS $12.00-$12.25 vs $12.09 Est; Sees Sales $5.750B-$5.850B vs $5.814B Est

    ResMed (NYSE:RMD) is looking for FY2027 Adj EPS of $12.00-$12.25 vs $12.09 analyst estimate. sees sales of $5.750 billion-$5.850 billion vs $5.814 billion analyst estimate.

79. ❖Oct 29, 12:05 PMnewsvia finnhub

    ResMed Q1 Adj. EPS $2.91 Beats $2.67 Estimate, Sales $1.415B Beat $1.392B Estimate

    ResMed (NYSE:RMD) reported quarterly earnings of $2.91 per share which beat the analyst consensus estimate of $2.67 by 8.99 percent. This is a 14.12 percent increase over earnings of $2.55 per share from the same period

80. ❖Oct 29, 9:00 AMnewsvia finnhub

    Ozlo Raises $22 Million Series B Led by Modi Ventures to Expand Its Sleep Technology Ecosystem

    Funding will accelerate product development, sleep research, and new technologies addressing a broader range of sleep and nighttime health needs BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ozlo, the sleep technology company behind Ozlo Sleepbuds®, announced it has raised $22 million in Series B funding led by Modi Ventures. Existing investors LifeArc, Artis Ventures, Resmed, Scrum Ventures, Drive by DraftKings, Wheelhouse 360, WISE Ventures, Niremia Collective, Accelerate Ventures, and World Solve

81. ❖Oct 28, 3:30 PMnewsvia finnhub

    If You Invested $1000 In ResMed Stock 20 Years Ago, You Would Have This Much Today

    ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.81%. Currently, ResMed has a market capitalization of $36.18 billion. Buying

82. ❖Oct 28, 8:15 AMnewsvia finnhub

    Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics

    Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.

83. ❖Oct 28, 1:42 AMnewsvia finnhub

    ResMed (RMD) Q3 earnings report preview: what to look for

    Medical device company ResMed (NYSE:RMD) will be reporting results this Thursday after market hours. Here’s what you need to know.

84. ?Oct 20, 2:50 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is up 2.27% today with no attributable headline, suggesting this is flow/positioning-driven rather than a catalyst event. The move is meaningful but not outsized enough to signal exhaustion on its own. The macro backdrop is mildly headwind: elevated 2Y rates (4.74, +2σ above trend) tend to pressure high-multiple healthcare device names like RMD via discount rate sensitivity, creating a modest fade risk. However, RMD is not a pure long-duration tech name, and rate sensitivity is secondary here. With only 55 minutes remaining until the forced close, there is limited runway for continuation — time decay on the setup is real. No reversal pattern is evident from the data provided, and absence of news does not disqualify the move. On balance, the momentum bias edges slightly in favor of continuation, but the combination of elevated rates, limited time, and no catalyst keeps conviction low. Assigning a marginal continuation probability just above the action threshold.

85. !Oct 20, 2:50 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is up 2.27% today with no attributable headline, suggesting this is flow/positioning-driven rather than a catalyst event. The move is meaningful but not outsized enough to signal exhaustion on its own. The macro backdrop is mildly headwind: elevated 2Y rates (4.74, +2σ above trend) tend to pressure high-multiple healthcare device names like RMD via discount rate sensitivity, creating a modest fade risk. However, RMD is not a pure long-duration tech name, and rate sensitivity is secondary here. With only 55 minutes remaining until the forced close, there is limited runway for continuation — time decay on the setup is real. No reversal pattern is evident from the data provided, and absence of news does not disqualify the move. On balance, the momentum bias edges slightly in favor of continuation, but the combination of elevated rates, limited time, and no catalyst keeps conviction low. Assigning a marginal continuation probability just above the action threshold.

86. ?Oct 16, 1:55 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is down 1.57% today, which is a moderate but not outsized move. There are no recent headlines to explain the selling, which limits conviction on whether this is informed flow or noise. The macro context (mortgage rates at 7.4%, 3.3σ above trend) is most directly relevant to Homebuilders, REITs, and Banks — RMD (ResMed, a medical devices/sleep apnea company) has minimal direct exposure to mortgage rate sensitivity, so the macro backdrop provides no meaningful tailwind or headwind for continuation. With 110 minutes remaining there is room for continuation, but the move is below the 2% threshold where momentum becomes more self-sustaining. Without a catalyst, volume confirmation, or sector-aligned pressure, this looks like a mid-session drift that could go either way. The absence of news cuts both ways — no catalyst to extend the move, but also no obvious fade trigger. The setup is marginally below the continuation threshold given the lack of sector alignment and the moderate magnitude of the move.

87. !Oct 16, 1:55 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is down 1.57% today, which is a moderate but not outsized move. There are no recent headlines to explain the selling, which limits conviction on whether this is informed flow or noise. The macro context (mortgage rates at 7.4%, 3.3σ above trend) is most directly relevant to Homebuilders, REITs, and Banks — RMD (ResMed, a medical devices/sleep apnea company) has minimal direct exposure to mortgage rate sensitivity, so the macro backdrop provides no meaningful tailwind or headwind for continuation. With 110 minutes remaining there is room for continuation, but the move is below the 2% threshold where momentum becomes more self-sustaining. Without a catalyst, volume confirmation, or sector-aligned pressure, this looks like a mid-session drift that could go either way. The absence of news cuts both ways — no catalyst to extend the move, but also no obvious fade trigger. The setup is marginally below the continuation threshold given the lack of sector alignment and the moderate magnitude of the move.

88. ?Oct 9, 3:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is up 1.61% today with no attributable news catalyst. The move is modest (below the 2-5% 'high conviction' threshold), leaving ambiguity about whether institutional flow is driving a sustained trend or this is noise. Macro context is unhelpful — elevated mortgage rates (7.4%, 3.8σ above trend) pressure homebuilders and REITs, but RMD is a medical devices/sleep health company (ResMed) with minimal direct exposure to mortgage rates or housing. With only 35 minutes remaining until the forced close, there is very limited time for further meaningful upside to develop. The move has likely already captured most of its intraday range, and late-session profit-taking or mean reversion is a realistic risk. No news to reinforce directional conviction. Given the time constraint and modest magnitude, this setup falls just below the threshold for a continuation trade.

89. !Oct 9, 3:10 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is up 1.61% today with no attributable news catalyst. The move is modest (below the 2-5% 'high conviction' threshold), leaving ambiguity about whether institutional flow is driving a sustained trend or this is noise. Macro context is unhelpful — elevated mortgage rates (7.4%, 3.8σ above trend) pressure homebuilders and REITs, but RMD is a medical devices/sleep health company (ResMed) with minimal direct exposure to mortgage rates or housing. With only 35 minutes remaining until the forced close, there is very limited time for further meaningful upside to develop. The move has likely already captured most of its intraday range, and late-session profit-taking or mean reversion is a realistic risk. No news to reinforce directional conviction. Given the time constraint and modest magnitude, this setup falls just below the threshold for a continuation trade.

90. ?Oct 7, 10:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    RMD is up 2.49% today with no headline catalyst visible, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in magnitude but not extreme. Macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.8σ above trend — RMD as a medical device company is modestly rate-sensitive but not a pure rate play, so this headwind is present but not dominant. With 305 minutes remaining (roughly full afternoon session), there is ample time for continuation. No reversal signal or fade pattern is indicated from available data. No news absence does not disqualify the trade. Balancing the real but unexplained momentum against a mildly unfavorable rate environment, this reads as a modest continuation setup — no strong reason to fade, but not enough clarity to assign high conviction.

91. !Oct 7, 10:40 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    RMD is up 2.49% today with no headline catalyst visible, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in magnitude but not extreme. Macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.8σ above trend — RMD as a medical device company is modestly rate-sensitive but not a pure rate play, so this headwind is present but not dominant. With 305 minutes remaining (roughly full afternoon session), there is ample time for continuation. No reversal signal or fade pattern is indicated from available data. No news absence does not disqualify the trade. Balancing the real but unexplained momentum against a mildly unfavorable rate environment, this reads as a modest continuation setup — no strong reason to fade, but not enough clarity to assign high conviction.

92. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with a durable competitive moat, but the evidence base here is thin — no news headlines, no insider activity, no options flow, and the 10-K/8-K filings contain no extractable metrics to confirm recent fundamental trajectory. The 10.6% dip from the 30-day high is moderate and may reflect sector-wide Health Care weakness (XLV ranked 6/11 by 30d rel-strength, underperforming SPY by ~4.2pts over 30 days), suggesting a macro/sector drag rather than company-specific impairment. However, the prior stop-out at $233.66 (well above current $216.79) and the elevated 10Y yield at 4.83% create structural headwinds for a high-multiple healthcare name like RMD. Earnings are 47 days away — non-imminent but close enough to limit near-term rebound runway before a binary event. Re-entry requires grounded evidence, not just drift; none is present here.

93. !Sep 11, 1:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with a durable competitive moat, but the evidence base here is thin — no news headlines, no insider activity, no options flow, and the 10-K/8-K filings contain no extractable metrics to confirm recent fundamental trajectory. The 10.6% dip from the 30-day high is moderate and may reflect sector-wide Health Care weakness (XLV ranked 6/11 by 30d rel-strength, underperforming SPY by ~4.2pts over 30 days), suggesting a macro/sector drag rather than company-specific impairment. However, the prior stop-out at $233.66 (well above current $216.79) and the elevated 10Y yield at 4.83% create structural headwinds for a high-multiple healthcare name like RMD. Earnings are 47 days away — non-imminent but close enough to limit near-term rebound runway before a binary event. Re-entry requires grounded evidence, not just drift; none is present here.

94. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    RMD is a fundamentally sound medical device leader in sleep apnea/respiratory care with no evidence of fundamental deterioration in the recent 10-K or 8-K filings. The 10.6% dip from the 30-day high does not reach the ≥15% mean-reversion threshold, and the drop appears sector-wide as Health Care (XLV) is underperforming SPY by ~4.24pts over 30 days (+1 signal). However, earnings are 47 days away (15-30 day zone does not apply, but the proximity still introduces uncertainty), there are no insider buys, no unusual call flow, and key macro headwinds are present: the 10Y at 4.83% is above the 4.5% threshold (-1, a headwind for a growth-oriented medical device name) and the T5YIFR is running 1.8σ above trend (-1 macro headwind). Net signal score is approximately 0 to +1, insufficient to trigger a confident buy without a cluster insider buy or unusual call flow as a confirming signal.

95. !Sep 11, 1:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    RMD is a fundamentally sound medical device leader in sleep apnea/respiratory care with no evidence of fundamental deterioration in the recent 10-K or 8-K filings. The 10.6% dip from the 30-day high does not reach the ≥15% mean-reversion threshold, and the drop appears sector-wide as Health Care (XLV) is underperforming SPY by ~4.24pts over 30 days (+1 signal). However, earnings are 47 days away (15-30 day zone does not apply, but the proximity still introduces uncertainty), there are no insider buys, no unusual call flow, and key macro headwinds are present: the 10Y at 4.83% is above the 4.5% threshold (-1, a headwind for a growth-oriented medical device name) and the T5YIFR is running 1.8σ above trend (-1 macro headwind). Net signal score is approximately 0 to +1, insufficient to trigger a confident buy without a cluster insider buy or unusual call flow as a confirming signal.

96. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with a durable competitive moat, but the evidence base here is thin — no news headlines, no insider activity, no options flow, and the 10-K/8-K filings contain no extractable metrics to confirm recent fundamental trajectory. The 10.6% dip from the 30-day high is moderate and may reflect sector-wide Health Care weakness (XLV ranked 6/11 by 30d rel-strength, underperforming SPY by ~4.2pts over 30 days), suggesting a macro/sector drag rather than company-specific impairment. However, the prior stop-out at $233.66 (well above current $216.79) and the elevated 10Y yield at 4.83% create structural headwinds for a high-multiple healthcare name like RMD. Earnings are 47 days away — non-imminent but close enough to limit near-term rebound runway before a binary event. Re-entry requires grounded evidence, not just drift; none is present here.

97. !Sep 11, 12:21 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with a durable competitive moat, but the evidence base here is thin — no news headlines, no insider activity, no options flow, and the 10-K/8-K filings contain no extractable metrics to confirm recent fundamental trajectory. The 10.6% dip from the 30-day high is moderate and may reflect sector-wide Health Care weakness (XLV ranked 6/11 by 30d rel-strength, underperforming SPY by ~4.2pts over 30 days), suggesting a macro/sector drag rather than company-specific impairment. However, the prior stop-out at $233.66 (well above current $216.79) and the elevated 10Y yield at 4.83% create structural headwinds for a high-multiple healthcare name like RMD. Earnings are 47 days away — non-imminent but close enough to limit near-term rebound runway before a binary event. Re-entry requires grounded evidence, not just drift; none is present here.

98. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    RMD is a fundamentally sound medical device leader in sleep apnea/respiratory care with no evidence of fundamental deterioration in the recent 10-K or 8-K filings. The 10.6% dip from the 30-day high does not reach the ≥15% mean-reversion threshold, and the drop appears sector-wide as Health Care (XLV) is underperforming SPY by ~4.24pts over 30 days (+1 signal). However, earnings are 47 days away (15-30 day zone does not apply, but the proximity still introduces uncertainty), there are no insider buys, no unusual call flow, and key macro headwinds are present: the 10Y at 4.83% is above the 4.5% threshold (-1, a headwind for a growth-oriented medical device name) and the T5YIFR is running 1.8σ above trend (-1 macro headwind). Net signal score is approximately 0 to +1, insufficient to trigger a confident buy without a cluster insider buy or unusual call flow as a confirming signal.

99. !Sep 11, 12:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    RMD is a fundamentally sound medical device leader in sleep apnea/respiratory care with no evidence of fundamental deterioration in the recent 10-K or 8-K filings. The 10.6% dip from the 30-day high does not reach the ≥15% mean-reversion threshold, and the drop appears sector-wide as Health Care (XLV) is underperforming SPY by ~4.24pts over 30 days (+1 signal). However, earnings are 47 days away (15-30 day zone does not apply, but the proximity still introduces uncertainty), there are no insider buys, no unusual call flow, and key macro headwinds are present: the 10Y at 4.83% is above the 4.5% threshold (-1, a headwind for a growth-oriented medical device name) and the T5YIFR is running 1.8σ above trend (-1 macro headwind). Net signal score is approximately 0 to +1, insufficient to trigger a confident buy without a cluster insider buy or unusual call flow as a confirming signal.

100. ?Sep 9, 9:45 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is down 1.57% today, which is a moderate but not dramatic move. Several factors temper continuation confidence: (1) The macro context shows the 5-year forward inflation rate (T5YIFR) at 1.8σ above trend, suggesting elevated rate sensitivity — RMD as a med-tech/device company with growth characteristics could face headwinds from rate-sensitive repricing, lending mild support to the downside move. However, (2) there are no news catalysts to anchor the move or suggest ongoing distribution, making it harder to assess whether this is informed selling or noise. (3) With 360 minutes remaining (6 hours), there is ample time for either continuation or reversal, which is neutral on timing. (4) The move magnitude at -1.57% is below the 2-5% threshold where conviction flow becomes more evident — this feels more like drift than a strong directional impulse. (5) Without volume data confirming heavy selling pressure, and with no headline catalyst, the base case leans toward mean reversion or consolidation rather than strong continuation. The rate-sensitive macro backdrop provides some marginal support for the downside, but not enough to confidently push probability above 0.5. Calling this a borderline pass — the setup does not clear the threshold for a continuation trade.

101. !Sep 9, 9:45 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is down 1.57% today, which is a moderate but not dramatic move. Several factors temper continuation confidence: (1) The macro context shows the 5-year forward inflation rate (T5YIFR) at 1.8σ above trend, suggesting elevated rate sensitivity — RMD as a med-tech/device company with growth characteristics could face headwinds from rate-sensitive repricing, lending mild support to the downside move. However, (2) there are no news catalysts to anchor the move or suggest ongoing distribution, making it harder to assess whether this is informed selling or noise. (3) With 360 minutes remaining (6 hours), there is ample time for either continuation or reversal, which is neutral on timing. (4) The move magnitude at -1.57% is below the 2-5% threshold where conviction flow becomes more evident — this feels more like drift than a strong directional impulse. (5) Without volume data confirming heavy selling pressure, and with no headline catalyst, the base case leans toward mean reversion or consolidation rather than strong continuation. The rate-sensitive macro backdrop provides some marginal support for the downside, but not enough to confidently push probability above 0.5. Calling this a borderline pass — the setup does not clear the threshold for a continuation trade.

102. ?Sep 8, 9:50 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is down 1.53% today, which is a moderate but not extreme move. There are no recent headlines to explain the move or suggest a catalyst that would drive further momentum. The macro context shows 5Y5Y forward inflation running 1.7σ above trend, which is a mild headwind for rate-sensitive names broadly — RMD as a medical device company has some rate sensitivity through valuation multiples, which marginally supports continuation of downside pressure. However, with 355 minutes remaining (roughly 6 hours), we are early in the session, meaning the move has ample time to either continue or reverse — this is a double-edged factor. The absence of a news-driven catalyst makes it harder to assign high conviction to continuation; the move could be sector rotation or light profit-taking rather than informed selling. The inflation backdrop provides a mild fundamental reason to expect continued pressure on growth/device names, but it is not a strong enough signal on its own to push probability above 0.55. With no reversal pattern yet established and time remaining to allow momentum to play out, I rate continuation probability at 0.50 — a borderline read that marginally favors the position given the system's risk-reward structure.

103. !Sep 8, 9:50 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is down 1.53% today, which is a moderate but not extreme move. There are no recent headlines to explain the move or suggest a catalyst that would drive further momentum. The macro context shows 5Y5Y forward inflation running 1.7σ above trend, which is a mild headwind for rate-sensitive names broadly — RMD as a medical device company has some rate sensitivity through valuation multiples, which marginally supports continuation of downside pressure. However, with 355 minutes remaining (roughly 6 hours), we are early in the session, meaning the move has ample time to either continue or reverse — this is a double-edged factor. The absence of a news-driven catalyst makes it harder to assign high conviction to continuation; the move could be sector rotation or light profit-taking rather than informed selling. The inflation backdrop provides a mild fundamental reason to expect continued pressure on growth/device names, but it is not a strong enough signal on its own to push probability above 0.55. With no reversal pattern yet established and time remaining to allow momentum to play out, I rate continuation probability at 0.50 — a borderline read that marginally favors the position given the system's risk-reward structure.

104. ?Sep 2, 11:05 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 1.88% intraday with no attributable news catalyst visible. The move is meaningful but sits at the lower end of the 2-5% 'real conviction' range, so it carries some weight but less than a larger surge would. With 280 minutes remaining (a full trading day essentially), there is ample time for continuation but also ample time for fade. The macro context shows the 5-year forward inflation rate (T5YIFR) is running 1.7σ above its 24-month trend, which creates a modestly unfavorable headwind for rate-sensitive sectors — RMD as a medical device/healthcare company has some rate sensitivity through its growth valuation profile and capital allocation story, meaning elevated inflation expectations could temper enthusiasm slightly. However, this is a second-order effect and not a strong reversal signal. No news headlines are present, which per guidelines is not a disqualifier. Balancing: moderate-sized move with no obvious catalyst, ample time remaining (a positive for continuation), slight macro headwind from elevated inflation expectations, and no reversal pattern evident mid-session. Net assessment is a modest lean toward continuation with no strong reason to fade.

105. !Sep 2, 11:05 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 1.88% intraday with no attributable news catalyst visible. The move is meaningful but sits at the lower end of the 2-5% 'real conviction' range, so it carries some weight but less than a larger surge would. With 280 minutes remaining (a full trading day essentially), there is ample time for continuation but also ample time for fade. The macro context shows the 5-year forward inflation rate (T5YIFR) is running 1.7σ above its 24-month trend, which creates a modestly unfavorable headwind for rate-sensitive sectors — RMD as a medical device/healthcare company has some rate sensitivity through its growth valuation profile and capital allocation story, meaning elevated inflation expectations could temper enthusiasm slightly. However, this is a second-order effect and not a strong reversal signal. No news headlines are present, which per guidelines is not a disqualifier. Balancing: moderate-sized move with no obvious catalyst, ample time remaining (a positive for continuation), slight macro headwind from elevated inflation expectations, and no reversal pattern evident mid-session. Net assessment is a modest lean toward continuation with no strong reason to fade.

106. ?Sep 1, 11:00 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is down 2.64% today with no attributable headline, suggesting this is likely sector/macro-driven selling or institutional repositioning. With 285 minutes remaining, there is ample time for continuation. The macro context shows 2-year yields elevated at 2.0σ above trend, which creates a valuation headwind for healthcare device names like RMD that carry growth premiums and are sensitive to discount rate increases. However, several factors temper conviction: (1) no specific catalyst means the move could be profit-taking or rotation rather than a structural re-rating, increasing fade risk into the close; (2) RMD is a defensive-leaning medical device company, which may attract buyers on dips absent a fundamental negative; (3) the move is meaningful but sits near the lower bound of the 2-5% significance range. On balance, the momentum and rate environment tilt the probability slightly toward continuation, but this is a marginal read — probability held at 0.52 reflecting genuine uncertainty with a modest lean toward the existing downward direction.

107. !Sep 1, 11:00 AMsignalseverity -0.03

     Agent 7 — Day Trader — day_trade_skipped

     RMD is down 2.64% today with no attributable headline, suggesting this is likely sector/macro-driven selling or institutional repositioning. With 285 minutes remaining, there is ample time for continuation. The macro context shows 2-year yields elevated at 2.0σ above trend, which creates a valuation headwind for healthcare device names like RMD that carry growth premiums and are sensitive to discount rate increases. However, several factors temper conviction: (1) no specific catalyst means the move could be profit-taking or rotation rather than a structural re-rating, increasing fade risk into the close; (2) RMD is a defensive-leaning medical device company, which may attract buyers on dips absent a fundamental negative; (3) the move is meaningful but sits near the lower bound of the 2-5% significance range. On balance, the momentum and rate environment tilt the probability slightly toward continuation, but this is a marginal read — probability held at 0.52 reflecting genuine uncertainty with a modest lean toward the existing downward direction.

108. ?Aug 28, 11:05 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 1.66% today, a modest but real move suggesting some positive flow. There are no headlines to attribute this to, which is common — the move itself reflects real buying pressure. RMD is a medical devices/sleep health company (ResMed), which has minimal direct sensitivity to mortgage rates, so the elevated MORTGAGE30US macro context is essentially neutral here. With 280 minutes remaining (roughly 4.5 hours), there is ample time for the move to extend into the close. However, the move is only 1.66%, sitting at the lower end of the meaningful-move threshold, which limits conviction on continuation — it could easily be profit-taken or fade without a catalyst. No reversal signals are noted. Overall, this is a mild momentum setup with no countervailing sector headwinds, warranting a slight lean toward continuation but with low conviction.

109. !Aug 28, 11:05 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 1.66% today, a modest but real move suggesting some positive flow. There are no headlines to attribute this to, which is common — the move itself reflects real buying pressure. RMD is a medical devices/sleep health company (ResMed), which has minimal direct sensitivity to mortgage rates, so the elevated MORTGAGE30US macro context is essentially neutral here. With 280 minutes remaining (roughly 4.5 hours), there is ample time for the move to extend into the close. However, the move is only 1.66%, sitting at the lower end of the meaningful-move threshold, which limits conviction on continuation — it could easily be profit-taken or fade without a catalyst. No reversal signals are noted. Overall, this is a mild momentum setup with no countervailing sector headwinds, warranting a slight lean toward continuation but with low conviction.

110. ▣Aug 26, 8:00 PMjournalmanual

     Agent 8 — Dip Buyer (Peer-Aware) closed long 5 @ $233.66 (+$186.86)

     Time stop: held 90 ≥ 90 days

111. ?Aug 25, 3:10 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 2.42% with no attributable headline, suggesting the move is driven by internal flow or sector rotation rather than a catalyst. With only 35 minutes remaining until the forced close, there is limited runway for continuation even if momentum is real. The macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend — RMD as a medical device/respiratory company is not a primary rate-sensitive name, so this is a mild headwind rather than a tailwind. No news means no fresh catalyst to sustain buying pressure into the close. The move is meaningful and represents real conviction, but the combination of very little time remaining and no identifiable driver caps the continuation probability at the base threshold. The system's bounded risk profile justifies a marginal long entry here.

112. !Aug 25, 3:10 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 2.42% with no attributable headline, suggesting the move is driven by internal flow or sector rotation rather than a catalyst. With only 35 minutes remaining until the forced close, there is limited runway for continuation even if momentum is real. The macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend — RMD as a medical device/respiratory company is not a primary rate-sensitive name, so this is a mild headwind rather than a tailwind. No news means no fresh catalyst to sustain buying pressure into the close. The move is meaningful and represents real conviction, but the combination of very little time remaining and no identifiable driver caps the continuation probability at the base threshold. The system's bounded risk profile justifies a marginal long entry here.

113. ?Aug 25, 1:31 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 1.85% today with no attributable headline, suggesting quiet but real institutional flow. The move is meaningful but not outsized — it sits below the 2-5% threshold where conviction would be more pronounced. The macro context (5Y5Y forward inflation 1.8σ above trend) is a mild headwind for rate-sensitive equities, and RMD as a med-tech/device name with durable earnings can be modestly rate-sensitive on valuation. However, this inflation signal is several days old and is already priced into the market to some degree. With 135 minutes remaining, there is ample time for the move to extend, which supports continuation. No reversal pattern is evident from the data provided, and no fade signal is present. In the absence of a clear reason to expect reversal and with reasonable time remaining, the default lean is modest continuation. Probability set just above threshold reflecting the mild macro headwind offset by time remaining and absence of bearish catalysts.

114. !Aug 25, 1:31 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 1.85% today with no attributable headline, suggesting quiet but real institutional flow. The move is meaningful but not outsized — it sits below the 2-5% threshold where conviction would be more pronounced. The macro context (5Y5Y forward inflation 1.8σ above trend) is a mild headwind for rate-sensitive equities, and RMD as a med-tech/device name with durable earnings can be modestly rate-sensitive on valuation. However, this inflation signal is several days old and is already priced into the market to some degree. With 135 minutes remaining, there is ample time for the move to extend, which supports continuation. No reversal pattern is evident from the data provided, and no fade signal is present. In the absence of a clear reason to expect reversal and with reasonable time remaining, the default lean is modest continuation. Probability set just above threshold reflecting the mild macro headwind offset by time remaining and absence of bearish catalysts.

115. ?Aug 25, 11:55 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 1.52% intraday with 230 minutes remaining until the forced close — ample time for continuation if momentum holds. The move is meaningful but below the 2-5% 'high conviction' threshold, suggesting moderate rather than strong directional flow. No headlines are present to explain the move, which is common; the absence of news does not negate the price signal. The macro headwind is notable: 5-year forward inflation expectations (T5YIFR) are running 1.8σ above trend, which is a mild negative for rate-sensitive sectors. RMD (medical devices/healthcare) is not the most rate-sensitive name, but elevated inflation expectations can create sector rotation pressure away from growth/defensive healthcare into cyclicals, providing a modest fade risk. Balancing: (1) the move has conviction enough to be real flow, (2) no reversal pattern or fade-off-highs signal is evident, (3) time remaining is substantial, but (4) the macro backdrop is slightly unfavorable and the move magnitude is modest. Net assessment: slight lean toward continuation, but no strong directional pressure warrants a higher probability. Probability set at 0.54 — take the trade with tight stop awareness.

116. !Aug 25, 11:55 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 1.52% intraday with 230 minutes remaining until the forced close — ample time for continuation if momentum holds. The move is meaningful but below the 2-5% 'high conviction' threshold, suggesting moderate rather than strong directional flow. No headlines are present to explain the move, which is common; the absence of news does not negate the price signal. The macro headwind is notable: 5-year forward inflation expectations (T5YIFR) are running 1.8σ above trend, which is a mild negative for rate-sensitive sectors. RMD (medical devices/healthcare) is not the most rate-sensitive name, but elevated inflation expectations can create sector rotation pressure away from growth/defensive healthcare into cyclicals, providing a modest fade risk. Balancing: (1) the move has conviction enough to be real flow, (2) no reversal pattern or fade-off-highs signal is evident, (3) time remaining is substantial, but (4) the macro backdrop is slightly unfavorable and the move magnitude is modest. Net assessment: slight lean toward continuation, but no strong directional pressure warrants a higher probability. Probability set at 0.54 — take the trade with tight stop awareness.

117. ▣Aug 23, 8:00 PMjournaltarget

     Agent 8 — Dip Buyer (Peer-Aware) closed long 5 @ $232.58 (+$181.46)

     Staged exit (1/2.0): close $232.58 ≥ target $230.03. Selling 5/10 sh, trailing remainder.

118. ?Aug 10, 3:16 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 3.49% with only 30 minutes remaining until the forced close. The move is meaningful in magnitude and represents real flow, but the critical limiting factor here is time — with just 30 minutes left, there is very limited runway to capture additional upside before the 3:45 PM ET cutoff. No news catalyst is present to explain the move, which cuts both ways (not a negative, but also no fundamental anchor to sustain buying). The macro context (T5YIE 1.6σ below trend) is mildly dovish and doesn't directly support or oppose a medtech/sleep device name like RMD. Late-session fade risk is elevated when a stock has already made a clean 3.5% move without an identifiable catalyst — institutional desks may use the final 30 minutes to trim or lock in profits rather than add. The combination of limited time remaining and elevated fade risk after a sizable unexplained gap pushes this just below the 0.5 threshold.

119. !Aug 10, 3:16 PMsignalseverity 0.03

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 3.49% with only 30 minutes remaining until the forced close. The move is meaningful in magnitude and represents real flow, but the critical limiting factor here is time — with just 30 minutes left, there is very limited runway to capture additional upside before the 3:45 PM ET cutoff. No news catalyst is present to explain the move, which cuts both ways (not a negative, but also no fundamental anchor to sustain buying). The macro context (T5YIE 1.6σ below trend) is mildly dovish and doesn't directly support or oppose a medtech/sleep device name like RMD. Late-session fade risk is elevated when a stock has already made a clean 3.5% move without an identifiable catalyst — institutional desks may use the final 30 minutes to trim or lock in profits rather than add. The combination of limited time remaining and elevated fade risk after a sizable unexplained gap pushes this just below the 0.5 threshold.

120. ?Aug 10, 9:45 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     The headline evidence is strongly contradictory to the current price action. The most recent headline (11:08 AM ET today) explicitly states RMD stock 'falls by 7% on soft FY27 outlook,' yet the current price is showing a +1.75% gain from prior close. This suggests either: (1) the current +1.75% reading is a temporary bounce/dead-cat rally after a sharp earlier drop that partially recovered, or (2) the price data and headlines are misaligned intraday. The earlier headline references margin pressures and soft outlook — fundamental negatives. With a soft FY27 guidance catalyst and margin pressure narrative dominating the session, any intraday bounce is likely to face heavy selling pressure into the close as momentum traders and institutions fade the relief rally. The macro context (T5YIE below trend) is mildly supportive of growth/risk assets but not enough to overcome a company-specific negative catalyst of this magnitude. With 360 minutes remaining there is ample time for the negative fundamental narrative to reassert itself. The setup reads as a fading bounce against a bearish fundamental backdrop — a clear reason to expect continuation of downward pressure rather than upward momentum.

121. !Aug 10, 9:45 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     The headline evidence is strongly contradictory to the current price action. The most recent headline (11:08 AM ET today) explicitly states RMD stock 'falls by 7% on soft FY27 outlook,' yet the current price is showing a +1.75% gain from prior close. This suggests either: (1) the current +1.75% reading is a temporary bounce/dead-cat rally after a sharp earlier drop that partially recovered, or (2) the price data and headlines are misaligned intraday. The earlier headline references margin pressures and soft outlook — fundamental negatives. With a soft FY27 guidance catalyst and margin pressure narrative dominating the session, any intraday bounce is likely to face heavy selling pressure into the close as momentum traders and institutions fade the relief rally. The macro context (T5YIE below trend) is mildly supportive of growth/risk assets but not enough to overcome a company-specific negative catalyst of this magnitude. With 360 minutes remaining there is ample time for the negative fundamental narrative to reassert itself. The setup reads as a fading bounce against a bearish fundamental backdrop — a clear reason to expect continuation of downward pressure rather than upward momentum.

122. ❖Aug 10, 7:08 AMnewsvia finnhub

     Resmed’s stock falls by 7% on soft FY27 outlook

     Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.

123. ❖Aug 10, 1:33 AMnewsvia finnhub

     RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts

     Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.

124. ❖Aug 9, 12:03 AMnewsvia finnhub

     ResMed Q4 Earnings Call Highlights

     ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electroni

125. ❖Aug 8, 10:50 PMnewsvia finnhub

     Top 50 High-Quality Dividend Growth Stocks For August 2026

     I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.

126. ?Aug 7, 6:03 PMdecisionconsidered

     Agent 20 — SIR Price/Volume — skip

     [exhaustion] The 20-day PV path tells a clear two-act story. From 2026-07-22 through 2026-08-05, the scatter drifted decisively up-and-right — closes climbed from $192.91 to a peak of $224.03 on routine-to-modestly-rising volume (971K–1.7M), characteristic of orderly accumulation. However, the final three sessions form a troubling sub-path: the price stalled in a tight $223–$224 cluster on Aug 4–5 (both 1.7M, well above the 1.3M ADV), and today Aug 7 delivers a -5.03% collapse to $212.02 on 3.4M shares — a z-score of 6.72 — the single largest volume bar in the 20-day window and a simultaneous price extreme reversal. This is a textbook exhaustion signature: the dot jumps sharply down-and-right to an unprecedented volume level while piercing the prior multi-session cluster, suggesting climactic selling or a large holder liquidating into the prior strength. Per the SIR methodology, a single exhaustion bar at a price extreme on unprecedented volume warrants caution and demands next-session confirmation before any bullish re-entry. Risks: The exhaustion read would be invalidated if the next 1–2 sessions recover above $218–$220 on declining volume, which would recast today's bar as a shakeout rather than a distribution climax. Additionally, the macro context (T5YIE 1.5σ below trend) suggests a deflationary/risk-off undertow that could amplify selling pressure in health-care equipment names like RMD, further pressuring the prior accumulation base.

127. ❖Aug 7, 3:05 PMnewsvia finnhub

     Stay informed with the top movers within the S&P500 index on Friday.

     Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.

128. ❖Aug 7, 1:54 PMnewsvia finnhub

     Dividend Champion, Contender, And Challenger Highlights: Week Of August 9

     Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.

129. ❖Aug 7, 1:05 PMnewsvia finnhub

     In today's session, there are S&P500 stocks with remarkable trading volume.

     In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Friday's session.

130. ❖Aug 7, 12:35 PMnewsvia finnhub

     Top S&P500 movers in Friday's session

     Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.

131. ❖Aug 7, 12:11 PMnewsvia finnhub

     RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

     RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.

132. ❖Aug 7, 11:12 AMnewsvia finnhub

     RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y

     Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

133. ❖Aug 7, 10:35 AMnewsvia finnhub

     What's going on in today's session: S&P500 gap up and gap down stocks

     Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

134. ?Aug 7, 10:20 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is down 5.06% post-earnings, a meaningful gap lower driven by the Q4 2026 results. Headlines confirm earnings beat estimates on EPS/revenue but the stock dropped — classic 'sell the news' reaction where the market was positioned for more or forward guidance disappointed. The earnings call transcript and highlights are already digested; no further catalyst to reverse. With 325 minutes remaining there is ample time for the move to continue, but the setup has some friction: (1) earnings beats with initial drops sometimes see partial intraday recovery as value buyers step in, (2) macro context shows 5Y inflation breakevens 1.5σ below trend, which is mildly risk-supportive and could provide a floor, (3) the stock is likely finding some support after a 5% drop on otherwise solid fundamental results. The balance of evidence supports mild continuation of the downside move — post-earnings gap-downs on 'sell the news' dynamics tend not to fully recover intraday — but the probability is modest given the beat on estimates limits aggressive further selling pressure.

135. !Aug 7, 10:20 AMsignalseverity -0.05

     Agent 7 — Day Trader — day_trade_skipped

     RMD is down 5.06% post-earnings, a meaningful gap lower driven by the Q4 2026 results. Headlines confirm earnings beat estimates on EPS/revenue but the stock dropped — classic 'sell the news' reaction where the market was positioned for more or forward guidance disappointed. The earnings call transcript and highlights are already digested; no further catalyst to reverse. With 325 minutes remaining there is ample time for the move to continue, but the setup has some friction: (1) earnings beats with initial drops sometimes see partial intraday recovery as value buyers step in, (2) macro context shows 5Y inflation breakevens 1.5σ below trend, which is mildly risk-supportive and could provide a floor, (3) the stock is likely finding some support after a 5% drop on otherwise solid fundamental results. The balance of evidence supports mild continuation of the downside move — post-earnings gap-downs on 'sell the news' dynamics tend not to fully recover intraday — but the probability is modest given the beat on estimates limits aggressive further selling pressure.

136. ❖Aug 7, 9:27 AMnewsvia finnhub

     S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today

     U.S. payrolls fell 23,000 in July, gutting September Fed hike odds. The S&P 500 hit a record, while gold jumped to a seven-week high.

137. ❖Aug 7, 9:08 AMnewsvia finnhub

     Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

     Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.

138. ?Jul 27, 7:02 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

139. !Jul 27, 7:02 AMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

140. ?Jul 24, 9:55 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is up 1.83% today, a meaningful but not outsized move. With 350 minutes remaining (well into the session with substantial time to close), there is room for the move to continue. No news headlines are present, which is neutral — absence of news does not negate momentum. The macro context shows a compressed yield curve (T10Y2Y at 2σ below trend), which is modestly supportive for defensive/healthcare names like RMD relative to cyclicals and banks. RMD as a medical device company in the sleep/respiratory space is not strongly rate-sensitive in a negative direction here. There are no reversal signals mentioned, no fade pattern indicated. The move is moderate and could reflect institutional accumulation or sector rotation into defensives given the macro backdrop. With no countervailing evidence and a bounded risk profile, a modest continuation probability is warranted, but the lack of volume data and relatively ordinary move magnitude keeps confidence from rising above the mid-range.

141. !Jul 24, 9:55 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     RMD is up 1.83% today, a meaningful but not outsized move. With 350 minutes remaining (well into the session with substantial time to close), there is room for the move to continue. No news headlines are present, which is neutral — absence of news does not negate momentum. The macro context shows a compressed yield curve (T10Y2Y at 2σ below trend), which is modestly supportive for defensive/healthcare names like RMD relative to cyclicals and banks. RMD as a medical device company in the sleep/respiratory space is not strongly rate-sensitive in a negative direction here. There are no reversal signals mentioned, no fade pattern indicated. The move is moderate and could reflect institutional accumulation or sector rotation into defensives given the macro backdrop. With no countervailing evidence and a bounded risk profile, a modest continuation probability is warranted, but the lack of volume data and relatively ordinary move magnitude keeps confidence from rising above the mid-range.

142. ?Jul 23, 6:04 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

143. !Jul 23, 6:04 PMsignalseverity 0.14

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

144. ?Jul 23, 6:03 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     RMD is a fundamentally sound company in the sleep apnea/respiratory care space with strong recurring revenue, but the Citigroup downgrade (sentiment -0.45) adds a meaningful headwind beyond simple macro noise. The macro environment shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which tends to favor defensives but can also signal growth concerns. The re-entry context is notable: the stock has fallen from the $218.40 stop-out price to $198.50, meaning the recovery thesis from the prior trade has not been validated — price is now below the prior exit level, suggesting the original bull thesis is still under pressure rather than reviving.

145. !Jul 23, 6:03 PMsignalseverity 0.14

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     RMD is a fundamentally sound company in the sleep apnea/respiratory care space with strong recurring revenue, but the Citigroup downgrade (sentiment -0.45) adds a meaningful headwind beyond simple macro noise. The macro environment shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which tends to favor defensives but can also signal growth concerns. The re-entry context is notable: the stock has fallen from the $218.40 stop-out price to $198.50, meaning the recovery thesis from the prior trade has not been validated — price is now below the prior exit level, suggesting the original bull thesis is still under pressure rather than reviving.

146. ?Jul 23, 7:02 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

147. !Jul 23, 7:02 AMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

148. ?Jul 22, 6:03 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     RMD is a fundamentally sound company in the sleep apnea/respiratory care space with strong recurring revenue, but the Citigroup downgrade (sentiment -0.45) adds a meaningful headwind beyond simple macro noise. The macro environment shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which tends to favor defensives but can also signal growth concerns. The re-entry context is notable: the stock has fallen from the $218.40 stop-out price to $198.50, meaning the recovery thesis from the prior trade has not been validated — price is now below the prior exit level, suggesting the original bull thesis is still under pressure rather than reviving.

149. ?Jul 22, 6:03 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

150. ?Jul 22, 7:02 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

151. ?Jul 21, 6:04 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     RMD is a fundamentally sound company in the sleep apnea/respiratory care space with strong recurring revenue, but the Citigroup downgrade (sentiment -0.45) adds a meaningful headwind beyond simple macro noise. The macro environment shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which tends to favor defensives but can also signal growth concerns. The re-entry context is notable: the stock has fallen from the $218.40 stop-out price to $198.50, meaning the recovery thesis from the prior trade has not been validated — price is now below the prior exit level, suggesting the original bull thesis is still under pressure rather than reviving.

152. ?Jul 21, 6:04 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

153. ?Jul 21, 7:02 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

154. ?Jul 20, 8:07 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     RMD is a fundamentally sound company in the sleep apnea/respiratory care space with strong recurring revenue, but the Citigroup downgrade (sentiment -0.45) adds a meaningful headwind beyond simple macro noise. The macro environment shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which tends to favor defensives but can also signal growth concerns. The re-entry context is notable: the stock has fallen from the $218.40 stop-out price to $198.50, meaning the recovery thesis from the prior trade has not been validated — price is now below the prior exit level, suggesting the original bull thesis is still under pressure rather than reviving.

155. ?Jul 20, 6:04 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

156. ?Jul 20, 9:35 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     RMD is down ~2.1% today with no headline catalyst visible, suggesting institutional selling or sector rotation rather than a news-driven spike that might fade. The move has meaningful conviction given the size, but it does not yet reach the 3-5% range that would indicate a stronger flush. Macro context shows the yield curve (T10Y2Y at 0.37, 1.8σ below trend) is flattening in a manner that favors defensives — RMD as a medtech/healthcare name could see mixed flows here; flattening slightly benefits defensives but the broader risk-off undertone that drives flattening can also weigh on growth-leaning medtech names. With 370 minutes remaining (roughly 6+ hours of session time, well before the 3:45 cutoff), there is ample time for the move to continue or extend. No reversal pattern is evident from the data provided — the move is directional and persistent so far. Absent a news catalyst to reverse sentiment and with sufficient time remaining, the base case is mild continuation of the downside drift into the close, though the lack of a clear catalyst and the relatively modest move size keeps confidence only marginally above 0.5.

157. ?Jul 20, 7:02 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     RMD is a fundamentally sound medical device company (sleep apnea/respiratory care) with no evidence of fundamental deterioration — the recent 8-K for the June 30 period shows no adverse metrics, and there is no guidance cut, covenant breach, or going-concern language. However, the drop is 10.8% (below the +1 signal threshold of ≥15%), and the primary catalyst appears to be an idiosyncratic negative: a Citigroup downgrade (sentiment -0.45) while the Health Care sector is essentially flat on the week (-0.06 vs SPY), meaning this is a single-stock issue rather than sector-wide noise. The net signal score is approximately -1 (no cluster buys, no unusual call flow, sector outperforming, drop <15%, no earnings headwind +1, macro neutral-to-slight-negative with 10Y at 4.56% above the ~4.5% threshold -1, idiosyncratic drop -1, no insider activity = net ~-1), which falls below the buy threshold.

158. ▣Jul 12, 8:00 PMjournalstop

     Agent 20 — SIR Price/Volume closed long 7 @ $196.30 (-$154.70)

     intraday stop sweep

159. ▣Jul 5, 8:00 PMjournaltarget

     Agent 4 — Dip Buyer (Frozen) closed long 5 @ $218.40 (+$160.25)

     Target hit: close $218.40 ≥ target $213.53

160. ▢Jul 5, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 7 @ $218.40

161. ▢Jun 30, 8:00 PMjournal

     Agent 7 — Day Trader opened long 14 @ $201.67

162. ▣Jun 30, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 14 @ $201.29 (-$5.32)

     EOD forced close — day trader never carries overnight

163. ▢Jun 16, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 5 @ $186.35

164. ▣Jun 3, 8:00 PMjournalstop

     options_momentum closed long 100 @ $5.29 (-$221.79)

     Stop: premium $5.29 ≤ trailing floor $8.41 (peak $11.21 × 0.75)

165. ▢May 28, 8:00 PMjournal

     options_momentum opened long 100 @ $7.51

166. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 5 @ $196.29

167. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 5 @ $196.29